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Abstract 
Assessment of the environmental impact, the risk posed by application of medicinal products 
for human and veterinary use is a legal obligation, and must be performed to evaluate and 
limit potential adverse effects of medicines on the environment. 
An environmental risk assessment (ERA) is performed in a stepwise approach in European 
Union, which starts with an initial screening phase (Phase I), aimed at identifying the 
environmental exposure of pharmaceuticals based on their potential for bioaccumulation and 
persistence in the environment. If, following this preliminary assessment, significant 
environmental exposure is anticipated, or if specific risks are identified due to compound-
specific characteristics, a number of studies should be performed (Phase II) based on the 
guidance documents issued by European Medicines Agency (EMA).  
The Phase II tests identify the fate of medicinal products in the environment and their 
potential effects on representative organisms (e.g. fish or daphnids, for the aquatic 
environment). For this purpose, the results of various internationally accepted test 
methodologies (laid down mainly by the Organisation for Economic Co-operation and 
Development, OECD) form the basis of the risk-assessment process, which may be further 
extended on a case-by-case basis, depending on the outcome of the assessment. 
However, several studies have been published revealing considerable residue levels in surface 
waters, in rivers and lakes throughout Europe that rise the question whether the current 
legislation and environmental risk assessment system of human and veterinary medicinal 
products are sufficiently protective. 
  
Introduction 
The pollution of water and soil with pharmaceutical residues is an emerging environmental 
concern worldwide. In Europe in August 2013, in the framework of the adoption of Directive 
2013/39/EU as regards priority substances in the field of water policy, the European 
Commission has been asked to develop a strategic approach to pollution of water by 
pharmaceutical substances by the end of 2015. BIO Intelligence Service carried out a study on 
the risks of environmental effects of medicinal products that together with other relevant 
studies and reports, provides the basis to develop the strategic approach (BIO Intelligence 
Service, 2013). 
There is increasing evidence that human and veterinary medicines are damaging wildlife. The 
report “Pharmaceuticals in the Environment: A growing threat to our tap water and wildlife” 
published by CHEMTrust in 2014 also highlights that medicines continuously pollute rivers 
and have harmed wild birds and fish (Warhurst, 2014). Other species have also been affected, 
and people are also worryingly exposed.  
This report also states that assessments of the environmental risks from human medicines in 
use before 30th October 2005 were not required and are often absent.  
Elizabeth Chadwick of the Cardiff University (UK), who was part of a three-year study 
looking at pharmaceuticals in otter tissue, expressed based on her research that as the human 
population grows and gets older, the level of pharmaceuticals being pumped into the 
environment is ever-increasing. It is one of the most serious threats to our environmental 
health. Post-launch coverage includes The Pharmaceutical Journal of 21st February 2015, and 
a detailed feature on pharmaceutical pollution in the April 2015 issue of ENDS Report 
(Owens, 2015). 
Over a dozen pharmaceuticals have been reported in the environment at many locations 
worldwide, including anti-inflammatory and analgesic agents (diclofenac, ibuprofen, 
naproxen, paracetamol, acetylsalicylic acid), antibiotics (sulphamethoxazole, trimethoprim, 
ciprofloxacin, ofloxacin, norfloxacin), the anti-epileptic carbamazepine, the lipid lowering 
clofibric acid as well as the residues of estrogenic substances, used in the contraceptive pill 
and to treat the menopause. (Warhurst, 2014). In the peer-reviewed literature recent studies 
have also demonstrated that despite the relatively low concentrations of pharmaceuticals in 
the environment (typically in sub-parts-per-billion levels) pharmaceuticals are of ecological 
concern due to their potential long-term adverse effects on humans and wildlife (Boxall et al, 
2004, Ankley et al., 2007, Zhou et al., 2008). 
Existing regulatory requirements of environmental risk assessment of 
medicinal products for human use 
The European Medicines Agency’s (EMA) guideline on the environmental risk assessment 
(ERA) of medicinal products for human use came into force in 2006 (EMA, 2006). In the 
scope of the guideline, it is stated that in accordance with Article 8(3) of Directive 
2001/83/EC, as amended, the evaluation of the potential environmental risks posed by 
medicinal products should be submitted, their environmental impact should be assessed and, 
on a case-by-case basis, specific arrangements to limit the impact should be considered. In 
any event, this impact should not constitute a criterion for refusal of a marketing 
authorisation. 
The EMA guidelines shall be applied to all new marketing authorization applications. 
However, vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates and lipids are 
exempted, since they are considered unlikely to result in significant risk to the environment. 
In addition, there are veterinary use of active pharmaceutical ingredients (APIs), and 
pharmaceutical substances consisting of genetically modified organisms (GMOs), that should 
also be considered in the environmental risk assessment.  
In Phase I of the risk assessment procedure described in the EMA guidance, the predicted 
environmental concentration (PEC) for surface water shall be calculated and the 
octanol−water partition coefficient (Kow) shall be measured (Table 1).  
 
 
Table 1: The phased approach in the environmental risk assessment 
 
 
 
If the PEC-value is equal to or above 0.01 μg/L, a Phase II assessment shall be performed. 
Active pharmaceutical ingredients (APIs) with a logKow > 4.5 are screened for PBT 
properties (Persistence, Bioaccumulation, Toxicity). APIs that are known a priori to affect 
reproduction of vertebrates or invertebrates at concentrations below 0.01 μg/L should also 
enter Phase II, following a tailored risk assessment strategy that addresses its specific 
mechanism of action. In Tier A of Phase II, physicochemical, fate, and effect studies 
(standard studies are recommended) are reviewed and the predicted no effect concentration 
(PNEC) for water, groundwater and microorganisms is calculated (Table 2).  
  
Table 2: Physicochemical, fate and effect studies recommended in Phase II Tier A 
 
 
 
If the ratio PECsurfacewater:PNECwater is above 1, an extended environmental fate and 
effect assessment, according to Tier B in Phase II, is required (Table 3). 
 
Table 3: Terrestrial fate and effects studies recommended in Phase II Tier B 
 
 
 
Regulatory requirements of environmental risk assessment of veterinary 
medicinal products 
In 1998 the EMEA issued a note for guidance on Environmental Risk Assessment for 
Veterinary Medicinal Products (VMP) other than GMO (genetically modified organism)-
containing and immunological products (EMEA, 1998). The guidance rests upon a logical, 
tiered approach with a cut-off trigger between a basic characterisation of the veterinary 
medicinal product and an in-depth assessment of its fate and ecotoxic effects. 
Phase I of the environmental risk assessment for a VMP starts with questions on the physical 
and chemical properties of the VMP, its use, dose route, frequency of dosing, animal 
husbandry and routes of excretion into the environment. It is assumed that VMPs with limited 
use and limited environmental exposure will have limited environ- mental effects and thus 
stop in Phase I. Phase I also identi fi es VMPs that require a more extensive environmental 
risk assessment under Phase II. Once a VMP has reached Phase II its predicted environmental 
concentration (PEC) is compared with its lowest effective concentration from standard 
ecotoxicity tests in soil and / or water to assess a probable environmental risk. After the toxic 
potential of the substance or its metabolites is assessed, the value is multiplied by an 
appropriate safety factor to create a predicted no effects concentration (PNEC). If the ratio of 
the predicted concentration to the predicted no effects concentration is greater than 1, further 
and more detailed studies on fate and effects of the VMPs have to be performed in order to 
refine the PEC as well as the PNEC. A decline of the expected environmental concentration is 
a function of hydrolysis, photolysis (chemical transformation) and biodegradation 
(mineralisation and biotransformation) of a VMP in the environment. The results from a 
short-term laboratory base set of ecotoxicity tests may be refined by long-term, semi-field or 
field data. At the end of the Phase II assessment, a VMP may not be expected to cause a 
significant harm to the environment or, if the PEC / PNEC ratio remains greater than 1, a risk 
to the environment is assumed. In the latter case, risk mitigation measures have to be linked 
with the authorisation for use of the product (Koschorreck et al., 2002).  
 
Table 4: Recently modified Environmental Risk Assessment Guidelines produced by EMA 
Committee for Medicinal Products for Veterinary Use (CVMP): 
 
Assessment of persistent, bioaccumulative and toxic (PBT) or very persistent and very 
bioaccumulative (vPvB) substances in veterinary medicinal products 
Assessing the toxicological risk to human health and groundwater communities from 
veterinary pharmaceuticals in groundwater 
Determining the fate of veterinary medicinal products in manure 
Environmental impact assessment for veterinary medicinal products in support of the VICH 
guidelines GL6 and GL38 
Higher-tier testing of veterinary medicinal products to dung fauna 
Plant testing strategy in the risk assessment for veterinary medicinal products 
VICH GL6 Environmental impact assessment (EIAS) for veterinary medicinal products - 
Phase I 
VICH GL38 Environmental impact assessments for veterinary medicinal products - Phase II 
Challenges and ways of improvement 
Pharmaceuticals have been reported in the environment at many locations worldwide. 
Although not limited to ethinyl estradiol, concerns about the effects of ethinyl estradiol 
(contraceptive pill and to treat the menopause) on wildlife included, as at many locations 
downstream of sewage treatment works, male fish have been feminised and have reduced 
sperm production. Many of these male fish abnormally make the female egg yolk protein and 
have eggs in their testes. Research has shown that ethinyl estradiol has contributed to causing 
these effects, often in combination with other hormones or hormone mimicking substance 
(Owens, 2015). 
Fish and other wildlife species may also be under threat from diclofenac (a non-steroid 
inflammatory drug, NSAID), because its concentration exceed the PNEC in many rivers 
worldwide. In the UK, a recent research paper, using modelled data and comparing with 
actual available data, suggested that this level might be exceeded in 4.5% of river reaches. 
Also, for example, a laboratory study has noted that environmentally realistic concentrations 
of diclofenac can impair osmo-regulation in the shore crab (Carcinus maenas) (Warhust, 
2014). 
Medicines used against parasites, for example the ivermectin, can be excreted in the faeces of 
treated animals and adversely affects invertebrate organisms that live in or feed on dung 
(Liebig et al., 2010). It can therefore also reduce the amount of food available to birds and 
bats. 
An EU funded research project (PHARMAS) has also highlighted that model predictions 
show that ciprofoxacin and levofloxacin (used for the treatment of urinary tract infections) 
may approach concentrations in some European rivers that could trigger ecological damage 
(Lamoree, 2011). 
Sándor et al. (2011) reported that only tetracyclines were detected in the studied Hungarian 
natural and waste waters in relatively low concentrations (<0.05-0.21 ng/ml) between 2007 
and 2010. Negligible amounts of two other antibiotics (sulfamethazin and nitrofuran) were 
detected in all water samples. Well detectable amount of NSAID were measured in the 
sampled influent waste water (ibuprofen, naproxen, ketoprofen and diclofenac: 2.55, 0.45, 
11.67 and 2.30 ng/ml, respectively). Their results have shown that considerable amount of 
NSAIDs might be decomposed through the waste water treatment (41.7-94.9%). The highest 
concentrations of NSAIDs were detected in all samples from fresh sludge (ibuprofen, 
naproxen, ketoprofen and diclofenac; 7.71, 27.61, 145.2 and 18.56 ng/ml, respectively). 
Negligible NSAID concentrations were found in the control samples of river Körös and 
oxbow lake of it. Results have shown that NSAIDs might be decomposed at least with 50% 
during the storage of sludge. As a conclusion, studied Hungarian waste waters are tainted with 
relatively low amounts of antibiotics and NSAIDs. However, these results might confirm that 
the adsorption and accumulation of antibiotics in sludge and sediments might be high and 
these processes can also damage the bacterial flora of biological wastewater treatment 
systems, which reduces the removal efficiency of other substances.  
As it is demonstrated, several studies have been published revealing considerable residue 
levels in surface waters, in rivers and lakes throughout Europe that rise the question whether 
the current legislation and environmental risk assessment system of human and veterinary 
medicinal products are sufficiently protective? 
On 26 March 2015, the EMA published a draft Questions and Answers Document (“Q&A 
Document“) for consultation concerning the EMA’s Guideline on the environmental risk 
assessment of medicinal products for human use (“EMA Guideline“). The purpose of the 
Q&A Document is to clarify and harmonise the use of the EMA Guideline. The draft Q&A 
Document, if adopted, will revise the current Q&A document that was adopted on 17 March 
2011. The Q&A Document was open for consultation until 30 June 2016. 
 
During the XV. Italian-Hungarian Symposium on Spectrochemistry: Pharmacological 
Research and Analytical Approaches (Pisa, 2016), several recommendations have been made 
to improve the ERA of medicinal products and allow to decrease the risk posed by 
pharmaceutical residues in the environment.  
These recommendations included the requirement of environmental risk assessment also for 
products put on the market before 2006, additional requirements to be included to the 
legislations to assess the risk for development of antibiotic resistance, refinement of the tiered 
approach, improvement the collection system of the used and remaining packages of 
medicinal products, up to perform combined toxicity assessments on active pharmaceutical 
ingredients with similar modes of action. 
It was recommended that environmental risks should be included in the risk-benefit analysis 
when a product is considered for market authorization. This would increase the importance of 
the environmental risk assessment and motivate pharmaceutical companies to perform the 
assessment on time. It was also recommended to update the environmental risk assessment of 
APIs, when significant new environmental information is available. 
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